---
title: "BPCR: Share price up, net income per share slightly down; portfolio diversified with new loans and full recovery from default"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300142520.md"
description: "Share price rose to $0.97, reducing buybacks, while net income per share for H1 2026 was just under $0.045, lower than last year due to fewer prepayments and no large one-time settlements. The portfolio is highly diversified, with new loans to Kestra, Idorsia, Mineralys, and Esperion, and the only historical default fully recovered.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-09-25T14:37:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300142520.md)
  - [en](https://longbridge.com/en/news/300142520.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300142520.md)
generator: "portal-rs"
---

# BPCR: Share price up, net income per share slightly down; portfolio diversified with new loans and full recovery from default

Share price rose to $0.97, reducing buybacks, while net income per share for H1 2026 was just under $0.045, lower than last year due to fewer prepayments and no large one-time settlements. The portfolio is highly diversified, with new loans to Kestra, Idorsia, Mineralys, and Esperion, and the only historical default fully recovered.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [ESPR.US](https://longbridge.com/en/quote/ESPR.US.md)
- [MLYS.US](https://longbridge.com/en/quote/MLYS.US.md)
- [KMTS.US](https://longbridge.com/en/quote/KMTS.US.md)

## Related News & Research

- [Will AHA Trial Data Change Mineralys Therapeutics (MLYS) Narrative](https://longbridge.com/en/news/300872529.md)
- [Mineralys Therapeutics CEO Jon Congleton disposes of $1,909,665 common shares](https://longbridge.com/en/news/300830702.md)
- [Mineralys to present lorundrostat Explore-OSA hypertension trial data at AHA Hypertension Scientific Sessions 2026](https://longbridge.com/en/news/300722541.md)
- [Mineralys director Brian Taylor Slingsby disposes of 104,320 common shares for $3 million](https://longbridge.com/en/news/300091813.md)
- [Mineralys says Transform-HTN extension data on lorundrostat set for late-breaking AHA 2026 presentation](https://longbridge.com/en/news/299938459.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**